SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Stocks That Stand Out For Nov. 23rd, 2009 Are XCEL, IDOI, EGOH, GETA, CCTR
[November 23, 2009]

Stocks That Stand Out For Nov. 23rd, 2009 Are XCEL, IDOI, EGOH, GETA, CCTR


(M2 PressWIRE Via Acquire Media NewsEdge) www.Standoutstocks.com: Stocks That Standout For Nov. 23rd, 2009 are Xcellink International Inc. (OTCBB: XCEL), IDO Security, Inc. (OTCBB: IDOI), Eagle Oil Holding Company, Inc. (OTCBB: EGOH), Genta Incorporated (OTCBB: GETA), China Crescent Enterprises, Inc. (OTCBB: CCTR) Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com _________________________________________________ Xcellink Defines Mobile Payments Marketplace as It Develops Applications and Rolls Out Its Patented Technology LAS VEGAS, NV, Nov 23, 2009 -- Xcellink International Inc. (OTCBB: XCEL), a developer of patented mobile payments and banking platforms, today commented on the growing marketplace for its technology as it develops its applications to interface with various smart phones including Apple's iPhone and Research in Motion's BlackBerry, and development contracts with companies such as the 3i Infotech Group of Companies, which includes Regulus Group, one of North America's largest payment processors.



Xcellink has the potential to become a major player in the next generation of customer payment systems and it now has patents in the United States, Canada, Malaysia, India, China, Philippines, ARIPO, Singapore, Australia, Vietnam, South Africa and New Zealand. This number represents over 60% of the world's population and, given the potential for mobile adoption, provides the Company with a potentially strong user base moving forward. Some examples follow.

According to TowerGroup, a financial research company, it is projected that mobile banking users in the USA will quintuple in the next four years, going from 10 million active users this year to more than 53 million in 2013.


China, where Xcellink also holds patents for its technologies, is also emerging as a very quick adopter of mobile payments. The number of China's mobile payment users reached 19.2 million at the end of June 2009, Interfax China reports, citing statistics released by local bankcard association China UnionPay. During the first six months of 2009, the number of mobile payment transactions hit 62.69 million, worth USD 2.49 billion, growing by 42.4 percent and 63.7 percent year-on-year, respectively.

And, based on gross transaction value estimates, the international mobile money transfer market is expected to be worth in excess of USD 65 billion by 2014. The report, by Juniper Research, revealed a new emerging sector for microcredits, saving accounts and insurance payments. Known as "sophisticated financial services" these services are entirely focused on developing countries where users do not have access to traditional banking or financial services or simply use alternative means of payment traditionally such as physically transporting cash, or storing cash savings at home.

A Company spokesperson for Xcellink noted, "Despite economic concerns, research is showing that consumers are wishing to manage their finances more closely and their desire for real-time access and control of their fiscal information is increasing the demand for mobile payments' technologies. The growth of mobile devices symbolizes an emerging, techno-savvy consumer market, revolutionizing many aspects of the consumer lifestyle, including mobile payments. And according to Mercator Advisory Group, more and more online storefronts are looking to increase their channel sales using mobile applications as a way to increase their reach and fuel growth as the economy moves out of recession. This provides Xcellink with an excellent base to promote its technology, both locally and globally as demand rises." About Xcellink Xcellink International Inc. is a developer of advanced platform-independent customer-centric payment systems and methodologies. Xcellink's patented system has the technical ability to replace all credit, debit, charge and smart cards, providing all functions of order, warehousing, delivery and payment for all types of goods and services in a customer-centric manner that is more efficient, economical, and secure than systems operating today. Xcellink's unique process enables customers, rather than the merchant, to initiate, control and pay for all transactions, without the need for credit cards, in real-time anywhere, anytime, and at a fraction of the cost of current transactions. Please visit www.xcellink.com Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of mentioned products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in reports filed with the Securities and Exchange Commission.

IDO Security, Inc. Hires Former Kodak Sales Executive to Initiate Distributor Activity in Latin America TEL AVIV, ISRAEL, Nov 23, 2009 -- IDO Security, Inc. (OTCBB: IDOI) (www.idosecurityinc.com), developer of the innovative MagShoe(TM) "shoes-on" weapons metal detection system, announced today that the company has retained Eduardo Bursztyn, former Regional Sales manager for Kodak-leaf in Latin America, to assist in creating its distribution system throughout the Latin American marketplace.

"We believe it is time to broaden our focus from Asia and Europe and begin to concentrate on this huge and untapped marketplace," said Dani Werber, International Sales and marketing manager for IDO Security.

Mr. Werber further stated, "According to the recently published report from the Security Industry Association (SIA), the security market is a $430 million annual market in Mexico alone and we can no longer ignore this market in its entirety." Mr. Bursztyn, a native Argentinian with over 25 years experience in this marketplace, stated, "The Latin America marketplace with its growing awareness of security issues as well as its growing population, makes it an ideal market for such an invaluable security tool as the MagShoe(TM). I look forward to bringing such a needed device to this market." Click here to visit social media version of this release.

Click here to visit the IDO Security social media newsroom.

About IDO Security: Headquartered in New York with a subsidiary in Israel, IDO Security designs, develops and markets the patented, UL-certified MagShoe(TM) weapons metal detection system. MagShoe(TM) fills a critical void in today's metal detectors by extending screening to the lower body and feet. MagShoe's unique "shoes-on" design maximizes security, thoroughness and accuracy while eliminating the need to remove shoes for increased convenience and safety. Ideal for security and loss prevention at virtually any facility, MagShoe(TM) is currently in use at international airports, cruise lines, government agencies, prisons and more. www.idosecurityinc.com Forward-Looking Statements: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based upon our current expectations about future events. These forward looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed as a result of a number of factors, including but no limited to, the sufficiency of existing capital resources, uncertainties related to the development of IDO's business plan, the ability to secure additional sources of financing, general economic conditions, the availability of competing products and the ultimate market acceptance of our products, changes in technology, legislative or regulatory changes that affect us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of IDO's Annual Report on Form 10-K for the year ended December 31, 2008, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Eagle Oil Holding Company Obtains Bridge Financing and Announces Plan to Commence Oil Pumping RENO, Nev., Nov 23, 2009 -- Eagle Oil Holding Company, Inc. (OTCBB: EGOH) ("Eagle Oil") is pleased to announce that it has received sufficient bridge financing to allow EGOH to commence pumping operations in its East Texas oil field. EGOH now expects to be able to restart the pumps on the four wells which have already been reconditioned as part of its plan to return all of its wells back to production. The Company is currently seeking additional funding to expedite its operating plan to test and then recondition an additional 10 to 20 wells in the upcoming months.

Eagle Oil is an independent growth-oriented energy company engaged in the exploration and production of oil through the development of repeatable, low geological risk, high potential projects in the active East Texas oil and gas region. The Company currently holds a 78% working interest in 173 wells located in the Historic Woodbine Oil Field in East Texas. Engineering reports show that EGOH's oil field contains over 12 million barrels of oil in place.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "should," "intends," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission.

Genasense(R) Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma Data Presented at International Melanoma Conference in Berlin BERKELEY HEIGHTS, N.J., Nov 20, 2009 -- --Results Follow Decision by Company to Continue Phase 3 AGENDA Trial for Overall Survival Genta Incorporated (OTCBB: GETA.OB) announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion. The data were featured this week in a presentation at the annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany.

Based on preclinical evidence of synergy, this study combined Genasense with temozolomide (Temodar(R); Schering Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane(R) (paclitaxel protein-bound particles for injectable suspension [albumen bound]; Abraxis Bioscience, Inc.). Previous results using a standard dose and schedule of Genasense (i.e., approximately 500 mg infused over 24 hours daily for 7 days) suggested this investigational combination was associated with clinical activity and good tolerability in 18 patients.

In the new schedule, Genasense was administered with the same chemotherapy as a brief IV infusion over 1-hour twice per week for 4 consecutive weeks at a dose of 900 mg. This schedule compresses approximately 48 hours of standard dosing into a brief 1-hour infusion.

To date, 10 patients with Stage IV metastatic melanoma have been accrued to this ongoing trial. Three patients achieved confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 to 40 weeks. One patient has maintained stable disease that has lasted 16 weeks, two patients have progressed, and four patients are too early to evaluate, having received only a single cycle. Only one episode (i.e., Grade 3 neutropenia) of any Grade 3-4 adverse event has been observed.

"With a preliminary disease control rate (defined as complete or partial responses plus stable disease lasting at least 3 months) of 67%, we view these data as very promising," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development. "Temozolomide is the active metabolite of dacarbazine that has been used in our Phase 3 trial in patients with advanced melanoma. I am pleased to confirm that Genta will continue the Phase 3, randomized, double-blind AGENDA trial in order to determine overall survival in that study. Finally, taxanes are being increasingly used in patients with metastatic melanoma. We intend to initiate a Phase 2 study of our proprietary oral taxane, tesetaxel, in advanced melanoma. We hope our comprehensive approach with these new medicines may improve the management of this devastating disease." About the AGENDA trial in advanced melanoma Genta has completed enrollment into AGENDA, a Phase 3, randomized, double-blind, placebo-controlled trial of Genasense in patients with advanced melanoma. Initial results did not show statistically significant differences in overall response or progression-free survival. The endpoints of durable response (complete or partial response lasting greater-than or equal to 6 months) and overall survival are too early to evaluate. An analysis for futility has been conducted for the survival endpoint, and the trial has passed that analysis. The Company has announced it plans to continue to follow patients on AGENDA in order to determine this endpoint.

About the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers This international conference is organized annually by the European Association of Dermatologic Oncology (EADO), which is a co-leader of the AGENDA trial. The meeting offers melanoma clinicians and researchers from multidisciplinary melanoma/skin cancer centers an opportunity to interact, establish collaborations, and set an agenda for the further evolution of melanoma care and research. Genta is a Co-Sponsor of the EADO meeting.

About Melanoma Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the U.S. Melanoma is the number one cause of cancer death in women aged 25 to 29. More information about melanoma can be accessed at the Melanoma Research Foundation: http://www.melanoma.org.

About Genasense Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta has pursued a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed oral formulations of the active ingredient in Ganite, which have completed preliminary clinical trials, as a potential treatment for diseases associated with accelerated bone loss. The Company is developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Genta intends to evaluate the clinical activity of tesetaxel in a range of human cancers. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipate", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with: -- the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency; -- the safety and efficacy of the Company's products or product candidates; -- the commencement and completion of any clinical trials; -- the Company's assessment of its clinical trials; -- the Company's ability to develop, manufacture, license, or sell its products or product candidates; -- the Company's ability to enter into and successfully execute any license and collaborative agreements; -- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, the Company's ability to obtain sufficient financing to fund the AGENDA trial, or the Company's risk of bankruptcy; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

China Crescent Enterprises, Inc. Releases 3rd Quarter Financial Report First Look Webcast to Review Record Net Income, Earnings per Share, and Suggested Fair Value Target Price per Share DALLAS, TX, Nov 20, 2009 -- China Crescent Enterprises, Inc. (OTCBB: CCTR) has released a first look, on-demand Webcast to review the recently filed third quarter 2009 financial results on SEC Form 10-Q.

The Company reported $30 million in revenue through the nine months ending September 30, 2009 and a record net income of $1.8 million compared to $517k in net income for the same period in 2008. The Company has forecasted profitable revenue growth in 2009 compared to 2008. The Company reported over $40 million in profitable revenue in 2008.

Today's Webcast is an initial review of the 3rd quarter results to include a review of record net income, earnings per share, and the suggested fair value target price per share, with further review scheduled to be released on Monday. A link to the on-demand Webcast is now available on the corporate website homepage www.chinacrescent.com titled 'China Crescent 3rd Quarter First Look Webcast'.

Sign Up to Receive Regular China Crescent Investor Updates China Crescent sends regular email updates to its opt-in, permission-based email database. Interested investors can easily, safely and quickly register to receive these communications directly on the corporate website homepage (www.chinacrescent.com). Recipients can manage their own email contact profile and safely unsubscribe at any time.

About China Crescent Enterprises, Inc. (www.chinacrescent.com) China Crescent Enterprises, Inc. reported over $40 million in profitable revenue in 2008. The Company is a technology leader in the rapidly developing Chinese market specializing today in software engineering, high quality software development and digital multimedia outsourcing services delivered to customers globally. At the same time, the firm is a systems integrator and value added reseller of major global hardware brands in the Chinese domestic market.

Headquartered in Dallas with operations in Shanghai and Beijing, China Crescent bridges the gap between Western and Eastern business cultures to assist Western clients in realizing the advantages of the high quality, low cost technology products and services available from China. China Crescent also assists Western clients in localizing products and services to realize the tremendous growth potential available by expanding into the Chinese Market.

"SAFE HARBOR STATEMENT" UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements that involve risks and uncertainties. The statements in this release are forward-looking statements that are made pursuant to safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results, events and performance could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause China Crescent's actual results in future periods to differ materially from results expressed or implied by forward-looking statements. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making investment decisions.

About Standoutstocks.com www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx ((Comments on this story may be sent to info@m2.com)) (c) 2009 M2 COMMUNICATIONS

[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: +1-203-852-6800, 800-243-6002

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2020 Technology Marketing Corporation. All rights reserved | Privacy Policy